Stratifying risk in acute myeloid leukemia, daratumumab plus chemotherapy in relapsed-refractory pediatric leukemias, and a method for creating genetically engineered platelets
Blood Podcast
00:00
Daratumumab as Bridge to Transplant and Safety Profile
About 62% of T-cell patients proceeded to transplant; toxicities were mainly hematologic and consistent with adult daratumumab data.
Play episode from 10:34
Transcript
